Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation

被引:32
作者
Patel, P. [1 ,2 ,3 ]
Gupta, P. K. C. [1 ,2 ,3 ]
White, C. M. J. [2 ,4 ]
Stanley, A. G. [4 ]
Williams, B. [5 ,6 ]
Tomaszewski, M. [2 ,3 ,4 ]
机构
[1] Univ Hosp Leicester NHS Trust, Dept Metab Med & Chem Pathol, Leicester, Leics, England
[2] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England
[3] Glenfield Gen Hosp, NIHR Leicester Cardiovasc Biomed Res Unit, Leicester LE3 9QP, Leics, England
[4] Univ Hosp Leicester NHS Trust, Leicester, Leics, England
[5] UCL, Inst Cardiovasc Sci, London, England
[6] Univ Coll London Hosp, Biomed Res Ctr, NIHR, London, England
基金
英国医学研究理事会;
关键词
TREATMENT-RESISTANT HYPERTENSION; SYMPATHETIC DENERVATION; ADHERENCE; URINE; ELIGIBILITY; MEDICATION; TRIAL; DRUGS;
D O I
10.1038/jhh.2015.103
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Renal denervation is a potential therapeutic option for resistant hypertension. A thorough clinical assessment to exclude reversible/spurious causes of resistance to antihypertensive therapy is required prior to this procedure. The extent to which non-adherence to antihypertensive treatment contributes to apparent resistance to antihypertensive therapy in patients considered for renal denervation is not known. Patients (n = 34) referred for renal denervation entered the evaluation pathway that included screening for adherence to antihypertensive treatment by high-performance liquid chromatography-tandem mass spectrometry-based urine analysis. Biochemical non-adherence to antihypertensive treatment was the most common cause of non-eligibility for renal denervation-23.5% of patients were either partially or completely non-adherent to prescribed antihypertensive treatment. About 5.9% of those referred for renal denervation had admitted non-adherence prior to performing the screening test. Suboptimal pharmacological treatment of hypertension and 'white-coat effect' accounted for apparently resistant hypertension in a further 17.7 and 5.9% of patients, respectively. Taken together, these three causes of pseudo-resistant hypertension accounted for 52.9% of patients referred for renal denervation. Only 14.7% of referred patients were ultimately deemed eligible for renal denervation. Without biochemical screening for therapeutic non-adherence, the eligibility rate for renal denervation would have been 38.2%. Non-adherence to antihypertensive treatment and other forms of therapeutic pseudo-resistance are by far the most common reason of 'resistant hypertension' in patients referred for renal denervation. We suggest that inclusion of biochemical screening for non-adherence to antihypertensive treatment may be helpful in evaluation of patients with 'resistant hypertension' prior to consideration of renal denervation.
引用
收藏
页码:368 / 373
页数:6
相关论文
共 50 条
  • [31] PREVENTION IS BETTER THAN CURE - THE ART OF AVOIDING NON-ADHERENCE TO ANTIRETROVIRAL TREATMENT
    Kwaan, Leith
    Kindra, Gurpreet
    Mdutyana, Lulama
    Coutsoudis, Anna
    SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE, 2010, (38) : 8 - 10
  • [32] Systematic review: non-adherence and non-persistence in intravitreal treatment
    Ehlken, Christoph
    Ziemssen, Focke
    Eter, Nicole
    Lanzl, Ines
    Kaymak, Hakan
    Lommatzsch, Albrecht
    Schuster, Alexander K.
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2020, 258 (10) : 2077 - 2090
  • [33] No margin for non-adherence: Probabilistic kaplan-meier modeling of imatinib non-adherence and treatment response in CML (ADAGIO study)
    Obeng-Kusi, Mavis
    MacDonald, Karen
    Van Lierde, Marie-Anne
    Lee, Christopher S.
    De Geest, Sabina
    Abraham, Ivo
    LEUKEMIA RESEARCH, 2021, 111
  • [34] Evaluation of Non-adherence to Anti-tuberculosis Treatment at a DOTS Clinic in Malaysia
    Sakuntala, Kumarasamy
    Ashah, Manghanmal
    Palanisamy, Sivanandy
    Krishnasamy, Karthikayini
    ASIAN JOURNAL OF PHARMACEUTICAL RESEARCH AND HEALTH CARE, 2021, 13 (01) : 30 - 42
  • [35] Systematic review: non-adherence and non-persistence in intravitreal treatment
    Christoph Ehlken
    Focke Ziemssen
    Nicole Eter
    Ines Lanzl
    Hakan Kaymak
    Albrecht Lommatzsch
    Alexander K. Schuster
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2020, 258 : 2077 - 2090
  • [36] Predictors of adherence and the role of primary non-adherence in antihormonal treatment of breast cancer
    Dragvoll, Ida
    Bofin, Anna M. M.
    Soiland, Havard
    Taraldsen, Gunnar
    Engstrom, Monica Jernberg
    BMC CANCER, 2022, 22 (01)
  • [37] Patient motivations for non-adherence to lung cancer screening in a military population
    Seastedt, Kenneth P.
    Luca, Michael J.
    Antevil, Jared L.
    Browning, Robert F.
    Mullenix, Philip S.
    Reoma, Junewai L.
    McKay, Sean A.
    JOURNAL OF THORACIC DISEASE, 2020, 12 (10) : 5916 - 5924
  • [38] Unintentional and intentional non-adherence to immunosuppressive medications in renal transplant recipients
    Griva, Konstadina
    Neo, Hui Ling Michelle
    Vathsala, Anantharaman
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2018, 40 (05) : 1234 - 1241
  • [39] Prescription refill records as a screening tool to identify antidepressant non-adherence
    Hansen, Richard A.
    Dusetzina, Stacie B.
    Dominik, Rosalie C.
    Gaynes, Bradley N.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 (01) : 33 - 37
  • [40] The effect of renal denervation in moderate treatment-resistant hypertension with confirmed medication adherence
    Ott, Christian
    Mahfoud, Felix
    Schmid, Axel
    Ewen, Sebastian
    Toennes, Stefan W.
    Meyer, Markus R.
    Helfer, Andreas G.
    Maurer, Hans H.
    Ditting, Tilmann
    Veelken, Roland
    Zivanovic, Ina
    Uder, Michael
    Boehm, Michael
    Schmieder, Roland E.
    JOURNAL OF HYPERTENSION, 2016, 34 (12) : 2475 - 2479